Dynavax Technologies Corporation (DVAX) News
Filter DVAX News Items
DVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DVAX News Highlights
- For DVAX, its 30 day story count is now at 4.
- Over the past 14 days, the trend for DVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AQST, DRUG and MIRM are the most mentioned tickers in articles about DVAX.
Latest DVAX News From Around the Web
Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.
Mirum (MIRM) Down on Failure of Mid-Stage Study on LivmarliMirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery. |
NextCure (NXTC) Down on Shelving Plans to Develop CandidateNextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same. |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year. |
Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 91.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's HowKiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates. |
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?Here is how Dynavax Technologies (DVAX) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year. |
Merck (MRK) to Acquire Private Neuroscience Company for $610MMerck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund. |
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx ConferenceDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET. |
Bayer (BAYRY) Stops Heart Drug Study Due to Lack of EfficacyBayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation. |
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study DataSpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls. |